

# Rebalanced hemostasis in liver disease: a misunderstood coagulopathy

Lara N. Roberts

King's College Hospital NHS Foundation Trust, Denmark Hill, London, United Kingdom

The combination of frequently abnormal hemostatic markers and catastrophic bleeding as seen with variceal hemorrhage has contributed to the longstanding misperception that chronic liver disease (CLD) constitutes a bleeding diathesis. Laboratory studies of hemostasis in liver disease consistently challenge this with global coagulation assays incorporating activation of the protein C pathway demonstrating rebalanced hemostasis. It is now recognized that bleeding in CLD is predominantly secondary to portal hypertension (rather than a coagulopathy) and additionally that these patients are at increased risk of venous thrombosis, particularly in the portal venous system. This narrative review describes the current understanding of hemostasis in liver disease, as well as the periprocedural management of hemostasis and anticoagulation for management of venous thromboembolism in patients with CLD.

## LEARNING OBJECTIVES

- Describe the changes leading to rebalanced hemostasis in CLD
- Recognize factors influencing periprocedural bleeding risk in patients with CLD
- Evaluate the need for anticoagulation of PVT in patients with liver disease and select the most suitable agent

## CLINICAL CASE

A 46-year-old woman with a new diagnosis of presumed alcohol-related cirrhosis presents to her local hospital with increasing abdominal swelling, pain, and jaundice. She had been admitted 1 year prior with alcohol withdrawal but did not attend planned hepatology outpatient reviews. She has continued to drink 0.5L of vodka daily. Initial laboratory investigation reveals the following: hemoglobin, 90g/L; platelets,  $43 \times 10^9$ /L; bilirubin, 199 $\mu$ mol/L; albumin, 26g/L; international normalized ratio (INR), 2.2; prothrombin time (PT), 33 seconds; and creatinine, 126 $\mu$ mol/L. The Child-Turcotte-Pugh class is C and Model for End Stage Liver Disease score is 25. She commences spironolactone but there is no improvement in ascites or weight, and her renal function further deteriorates. Therapeutic paracentesis is planned and the medical team requests authorization of fresh-frozen plasma (FFP) (aiming for an INR of <1.5) to proceed.

The natural history of chronic liver disease (CLD) is characterized by phases of stable cirrhosis progressing to acute decompensation (AD), from which patients may recover or progress to multiorgan failure, known as acute-on-chronic

liver failure (ACLF).<sup>1</sup> Most patients admitted to the hospital are in a state of AD, often following a precipitating event. Common complications pertain to liver failure or portal hypertension and comprise jaundice, encephalopathy, ascites, and variceal bleeding. Although bleeding is common in liver disease, it is now recognized that most spontaneous bleeding events are predominantly gastrointestinal (GI) and secondary to portal hypertension (refer to Table 1 for incidence).<sup>2-4</sup>

The liver has a key role in the synthesis of both pro- and anticoagulant proteins, along with pro- and antifibrinolytics and thrombopoietin.<sup>9</sup> Portal hypertension in CLD leads to splenomegaly and thrombocytopenia. Progression of CLD with synthetic failure is accompanied by prolongation of PT.<sup>10</sup> As PT simply measures time to first detection of clot in plasma following activation with tissue factor and calcium, it does not reflect in vivo hemostasis in patients with CLD in which natural anticoagulants (protein C, protein S, and antithrombin) are reduced in parallel, and it does not detect increased factor VIII and von Willebrand factor. Global coagulation assays, such as thrombin generation incorporating activation of the protein C pathway, demonstrate that patients with CLD have rebalanced hemostasis with some evidence of hypercoagulability. With increasing disease severity (as in ACLF), wide interindividual variation

**Table 1. Incidence of bleeding and portal vein thrombosis in CLD reported in prospective studies**

| Study setting                                             | Study design                                   | Participants, n | Child-Pugh class A, n (%) | Incidence                                                                                                                                              |
|-----------------------------------------------------------|------------------------------------------------|-----------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bleeding                                                  |                                                |                 |                           |                                                                                                                                                        |
| Italy, 2012–2014 <sup>3</sup>                             | Prospective, multicenter                       | 280             | 53                        | Overall: 5.5%/year<br>Major: 3.6%/year<br>Minor: 1.9%/year<br>Portal hypertensive: ~3.3%/year<br>Nonvariceal GI: 1.9%/year<br>Intracranial: 0.17%/year |
| United States, December 2009 to January 2010 <sup>4</sup> | Prospective, single-center hospitalized cohort | 83              | 0                         | Overall: 40%<br>Variceal: 17%<br>Nonvariceal GI: 12%                                                                                                   |
| Portal vein thrombosis                                    |                                                |                 |                           |                                                                                                                                                        |
| Italy, 2012–2014 <sup>5</sup>                             | Prospective, multicenter                       | 753             | 397 (53)                  | 6.1/100 patient years                                                                                                                                  |
| No PVT at enrollment                                      |                                                | 692             |                           | 4.1                                                                                                                                                    |
| Prior PVT at enrollment                                   |                                                | 61              |                           | 18.9                                                                                                                                                   |
| France/Belgium, 2000–2006 <sup>6</sup>                    | Prospective, multicenter                       | 1243            | 863 (69)                  | 1y: 4.6%<br>Cumulative 5y: 10.7%                                                                                                                       |
| France, 2014–2017 <sup>7</sup>                            | Prospective, single center                     | 108             | 75 (77)                   | 1y: 10.8%                                                                                                                                              |
| Portugal, 2014–2019 <sup>8</sup>                          | Prospective, single center                     | 241             | 184 (76)                  | 1y: 3.7%<br>Cumulative 3y: 7.6%                                                                                                                        |

Modified from Roberts and Bernal (2020)<sup>2</sup> with permission from Thieme.

in thrombin generation potential is seen with a more precarious hemostatic balance.<sup>10–12</sup> Similarly, thrombocytopenia and platelet dysfunction are countered by increased von Willebrand factor, with increased high molecular weight multimers due to reduced ADAMTS13.<sup>13,14</sup> The changes in hemostasis associated with CLD are summarized in Table 2.

### Periprocedural bleeding risk

It has been repeatedly demonstrated over the past 40 years that neither prolonged PT/INR nor thrombocytopenia independently predict periprocedural bleeding.<sup>9,15–17</sup> These parameters continue to be measured with attempts at correction common in this setting, despite potential for harm associated with transfusion.<sup>18,19</sup>

Procedural bleeding risk in patients with CLD is not well defined; variable practice in attempting to correct hemostatic markers and a lack of consistent definition for major bleeding are key contributory factors.<sup>20</sup> It is proposed that procedures with an incidence of major bleeding of more than 2% or bleeding with potential to cause organ damage/death be considered high risk.<sup>20</sup> Ascites is a frequent complication of CLD, developing in approaching two-thirds of patients within 10 years of cirrhosis diagnosis.<sup>21</sup> Therapeutic paracentesis is recommended as first-line treatment for large-volume ascites, and this scenario is commonly encountered. The risk of bleeding following paracentesis is low, estimated at 0.2%.<sup>22</sup> Acute kidney injury is a recognized independent risk factor for postparacentesis hemoperitoneum.<sup>23</sup>

### Prophylactic hemostatic interventions

Despite evidence that major surgery such as liver transplantation can be safely performed without correcting abnormal hemostatic markers,<sup>24</sup> attempts at correction remain common

in the procedural setting.<sup>18,19</sup> In Spain, a national survey (of predominantly hepatologists, 69%) from 2017 reported the majority of respondents would attempt to correct PT prior to major procedures, with 17% also attempting to correct prior to low-risk procedures.<sup>19</sup> Almost all respondents reported attempting to correct thrombocytopenia prior to major surgery, with 35% also attempting to correct prior to low-risk procedures, predominantly using a threshold for platelets of less than  $50 \times 10^9/L$ . However, attempts to correct thrombocytopenia and coagulopathy with transfusion are associated with additional risks. Administration of a “therapeutic” volume of FFP predisposes to both transfusion-associated circulatory overload and transfusion-related acute lung injury.<sup>25</sup> Furthermore, due to subsequent increases in portal venous pressure,<sup>26</sup> FFP administration may paradoxically increase the risk of bleeding (eg, during endoscopic variceal band ligation or transjugular portosystemic shunt placement). In addition, laboratory studies demonstrate that patients with CLD have preexisting normal to hypercoagulable profiles, with FFP transfusion having a minimal impact on improving PT but increasing hypercoagulability.<sup>27,28</sup> Platelet transfusion results in variable platelet count increment,<sup>28,29</sup> and randomized controlled trials of platelet transfusion in other populations (eg, intracerebral bleeding) are associated with worse outcomes.<sup>30</sup> Thrombopoietin receptor agonists have been demonstrated to better correct platelet count prior to elective procedures.<sup>31,32</sup> However, the seminal studies included both low- and high-risk procedures and lacked clinically important primary outcomes. Meta-analysis suggests their use may reduce periprocedural bleeding.<sup>33</sup>

Given the risks association with plasma transfusion and lack of evidence to demonstrate benefit, correction of prolonged PT prior to paracentesis has been advised against since 2003 by international societies. Recommendations for high-risk bleeding

**Table 2. Summary of hemostatic changes in CLD and laboratory evidence supporting rebalanced hemostasis**

| Characteristic | Factors associated with bleeding                                                                                                                                              | Factors associated with thrombosis                                                                                                               | Laboratory evidence to support rebalanced hemostasis                                                                                                                                                                   |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Platelets      | <ul style="list-style-type: none"> <li>• Thrombocytopenia</li> <li>• Platelet dysfunction</li> <li>• Anemia</li> </ul>                                                        | <ul style="list-style-type: none"> <li>• ↑ vWF</li> <li>• ↓ADAMTS13</li> <li>• ↑Platelet activation</li> <li>• Endothelial activation</li> </ul> | <ul style="list-style-type: none"> <li>• Weak</li> <li>• Difficult to replicate platelet-endothelial interaction in laboratory setting</li> </ul>                                                                      |
| Coagulation    | <ul style="list-style-type: none"> <li>• ↓FII, V, VII, IX, X, XI</li> <li>• ↓Fibrinogen (in AD, ACLF)</li> <li>• ↓FXIII</li> <li>• ↓Rates of fibrin polymerization</li> </ul> | <ul style="list-style-type: none"> <li>• ↓Protein C, protein S, antithrombin</li> <li>• ↑FVIII</li> <li>• ↓Fibrin clot permeability</li> </ul>   | <ul style="list-style-type: none"> <li>• Thrombin generation normal to increased when measured with protein C pathway activation</li> <li>• Weak evidence for rebalancing of fibrin clot strength/stability</li> </ul> |
| Fibrinolysis   | <ul style="list-style-type: none"> <li>• ↑tPA (not rebalanced by ↑PAI-1)</li> <li>• ↓α2-Antiplasmin</li> <li>• ↓TAFI</li> </ul>                                               | <ul style="list-style-type: none"> <li>• ↓Plasminogen</li> </ul>                                                                                 | <ul style="list-style-type: none"> <li>• Uncertain; both hyper/hypofibrinolysis seen in ACLF, potentially reflecting the delicate nature of rebalance</li> </ul>                                                       |

Adapted from Northup et al<sup>20</sup> with permission from Wiley.

ADAMTS13, a disintegrin and metalloproteinase thrombospondin type 1 motif; F, factor; PAI-1, plasminogen activator inhibitor 1; TAFI, thrombin activatable fibrinolysis inhibitor; tPA, tissue plasminogen activator; vWF, von Willebrand factor.

procedures are summarized in Table 3.<sup>20,34-36</sup> Vitamin K deficiency may be relevant in those with poor diet and/or malabsorption, and a single dose of 10mg more than 12 hours prior to interventions in such patients is advocated by some.<sup>35,36</sup>

### CLINICAL CASE (Continued)

This patient received a single dose of vitamin K on admission with no improvement in the PT. After reassuring the medical team that the procedural bleeding risk of paracentesis is low and that PT/INR and platelet count are not a measure of bleeding risk, therapeutic paracentesis is performed under ultrasound guidance without complication.

She recovers from this acute episode of decompensation and remains abstinent from alcohol following hospital discharge. On routine screening ultrasound for hepatocellular carcinoma 2 years later, she is diagnosed with occlusive portal vein thrombosis (PVT) extending to the superior mesenteric venous junction. The spleen is enlarged (20cm), and the patient has the following laboratory values: hemoglobin, 110g/L; platelets,  $57 \times 10^9$ /L; bilirubin, 16μmol/L; albumin, 40g/L; PT, 18 seconds; INR, 1.3; sodium, 138μmol/L; and creatinine, 116μmol/L. She is Child-Turcotte-Pugh class A, and Model for End Stage Liver Disease score is 13. An upper GI endoscopy performed during the previous admission revealed mild portal hypertensive gastropathy with no esophageal varices. The medical team seek advice on the role for anticoagulation in the context of thrombocytopenia.

### Venous thromboembolism in CLD

PVT is the most common thrombotic event affecting patients with CLD, with its prevalence reported in up to 26% in those listed for liver transplantation and increasing in parallel with disease severity.<sup>38</sup> CLD is also associated with an increased risk of deep vein thrombosis (DVT) and pulmonary embolism. A meta-analysis of predominantly retrospective cohort studies reported

cirrhosis was associated with an increased odds ratio for venous thromboembolism (VTE) of 1.7 (95% CI, 1.3-2.2).<sup>39</sup> The incidence of PVT in recent prospective studies is summarized in Table 1. The Italian observational cohort of 753 patients with cirrhosis reported an incidence rate of 6 per 100 patient years.<sup>5</sup> Of note, half of the events were asymptomatic and detected on routine screening for hepatocellular carcinoma. Those with prior PVT at study entry had a significantly higher rate of PVT compared with those without (18.9 vs 4.0 per 100 patient years).<sup>5</sup> The only independent risk factors for PVT identified in this study were previous PVT and degree of thrombocytopenia (with lower counts associated with increased risk). A further prospective observational cohort of 241 patients with cirrhosis reported a cumulative incidence of 3.7% and 7.6% at 1 and 3 years, respectively.<sup>8</sup> Thrombocytopenia and previous decompensation were identified as independent predictors of PVT. Of note, in both cohorts, most patients were Child-Pugh class A (see Table 1).

This scenario illustrates again that conventional laboratory tests do not reflect the underlying hemostatic milieu in patients with liver disease. The paradoxical increase in PVT risk associated with thrombocytopenia likely reflects increasing severity of both liver disease and portal hypertension with reduced portal venous flow.<sup>8,40</sup> Only a single, small retrospective study (n=53) has examined the influence of hypercoagulability measured with thrombin generation on PVT risk.<sup>41</sup> Patients with baseline "thrombomodulin resistance" (defined as an endogenous thrombin potential ratio >95th percentile of normal controls) had an 8-fold increase in risk of PVT over 4 years. Local hypercoagulability mediated by bacterial translocation, inflammation, and endotoxemia are proposed as additional contributors but have not been confirmed in prospective studies.<sup>42</sup>

### Anticoagulation in CLD

The need for anticoagulation in this scenario of incidental PVT in the absence of intestinal ischemia or planned liver transplantation (in which anastomosis may be compromised) is uncertain. A recent meta-analysis of 33 studies comprising 1696 patients with PVT reported spontaneous complete recanalization in 18%

**Table 3. Thresholds for coagulation parameters prior to high-risk procedures in patients with CLD**

| Characteristic | AASLD 2021 <sup>20</sup> | ACG 2020 <sup>37</sup>     | AGA 2019 <sup>35</sup>     | SIR 2019 <sup>36</sup>     |
|----------------|--------------------------|----------------------------|----------------------------|----------------------------|
| PT/INR         | Do not correct           | Do not correct             | Do not correct             | INR >2.5*                  |
| Platelet count | Do not correct           | >50×10 <sup>9</sup> /L     | >50×10 <sup>9</sup> /L     | >30×10 <sup>9</sup> /L     |
| Fibrinogen     | Do not correct           | No specific recommendation | >1.2g/L                    | >1g/L                      |
| VHA            | Do not use routinely     | May be useful              | No specific recommendation | No specific recommendation |

\*Give vitamin K if INR >2.5; do not use FFP/prothrombin complex concentrate.

Table adapted from Northup et al<sup>20</sup> with permission from Wiley.

AASLD, American Association for the Study of Liver Disease; ACG, American College of Gastroenterology; AGA, American Gastroenterology Association; SIR, Society of Interventional Radiology; VHA, viscoelastic hemostatic assay.

of patients (n=33/180) not receiving anticoagulation. However, anticoagulation was associated with a significant 2-fold improvement in overall and complete recanalization rates compared with no anticoagulation. The risk of thrombus progression was also significantly reduced (risk ratio [RR], 0.26; 95% CI, 0.14-0.49). Six studies reported overall survival, with anticoagulation associated with improvement (RR, 1.11; 95% CI, 1.03-1.21).<sup>43</sup> There are clearly a number of limitations to this analysis. In our case, given the thrombus is occlusive and extends to the mesenteric junction, anticoagulation is likely to be beneficial in preventing further extension to the mesenteric vasculature and achieving recanalization, with potential reduction in portal hypertension (given the lack of portosystemic collateral circulation). Guidelines recommend obtaining cross-sectional imaging (computed tomography/magnetic resonance imaging) to confirm the diagnosis and extent of thrombosis, as well as to exclude malignant obstruction prior to treatment initiation.<sup>20</sup> There is a clear role for anticoagulation in patients with symptomatic PVT to prevent progression and intestinal ischemia.

The principal concern in anticoagulating patients with liver disease is the concomitant increased risk of bleeding. In the aforementioned meta-analysis, the pooled overall rate of bleeding associated with anticoagulation from 19 studies was 2.8%, with fatal bleeding 0.7% (from 25 studies).<sup>43</sup> The pooled rate of esophageal variceal bleeding from 17 studies was 2%. The use of anticoagulation did not increase the risk of bleeding (RR, 0.78; 95% CI, 0.47-1.3) from 4 studies reporting outcomes in those both on and off anticoagulation, and interestingly, anticoagulation was associated with a reduced risk of both upper GI and variceal bleeding (RR, 0.26; 95% CI, 0.11-0.65).<sup>43</sup> These data suggest anticoagulation does not increase the risk of variceal hemorrhage (and may in fact reduce the risk, potentially by reducing portal hypertension). It is recommended that upper GI endoscopy be performed to identify and enable treatment of high-risk varices.<sup>20</sup> In practice, anticoagulation can be initiated while awaiting further endoscopic evaluation. Endoscopic variceal banding is a low bleeding risk procedure,<sup>20</sup> with procedural bleeding uncommon and the majority of bleeding secondary to band ulceration, presenting some days later.<sup>15,44</sup> A single observational study found no increased bleeding risk associated with use of low molecular weight heparin (LMWH) (169 procedures in 80 patients) at the time of variceal band ligation.<sup>45</sup> However, proceduralists may temporarily interrupt anticoagulation following variceal banding when the perceived bleeding risk due to secondary band ulceration is thought to outweigh the risk of thrombosis extension.

Thrombocytopenia is a recognized risk factor for bleeding with anticoagulation; a small observational cohort reported a platelet count of less than 50×10<sup>9</sup>/L as a predictor for bleeding.<sup>46</sup> In these patients, I consider initiating LMWH at prophylactic to intermediate doses and titrate the dose as tolerated. I favor intermediate doses for symptomatic and/or extensive PVT. For limited extent/asymptomatic events in which a decision for anticoagulation is made, I favor prophylactic doses at initiation. Severe thrombocytopenia (<30×10<sup>9</sup>/L) is uncommon, and in such cases, I would look for and treat contributing factors but still consider prophylactic LMWH on a case-by-case basis. If the platelet count improves, therapeutic doses can then be used. As this patient has a platelet count more than 50×10<sup>9</sup>/L, full-dose anticoagulation should be used.

For venous thromboembolism in patients without CLD, direct oral anticoagulants (DOACs) are now the agents of choice due to their predictable pharmacokinetics, eliminating the need for routine drug monitoring and favorable safety profile.<sup>47</sup> Characteristics of available anticoagulants are summarized in Table 4. Of note, patients with CLD were excluded from the randomized controlled trials establishing their efficacy in VTE, and there is little evidence for use of DOACs in treatment of PVT in cirrhosis. The use of DOACs is not recommended in patients with increased severity of CLD (see Table 4). A recent systematic review identified 5 retrospective cohort studies comprising 239 patients with CLD treated for DVT, splanchnic vein thrombosis, or atrial fibrillation.<sup>48</sup> The analysis suggests comparable efficacy and safety but is limited by the small sample size and retrospective nature of the studies. A small randomized controlled trial (n=80) in Egypt compared rivaroxaban 10mg daily with warfarin for treatment of acute PVT in patients with compensated hepatitis C cirrhosis (predominantly after splenectomy) for a variable treatment duration based on thrombus extent and recanalization.<sup>49</sup> Patients were monitored fortnightly with ultrasound imaging with a primary outcome of complete recanalization. The primary outcome was achieved in significantly more patients receiving rivaroxaban (85% vs 45%), with recanalization occurring at a mean of 2.5 months. There was no major bleeding reported in the rivaroxaban arm and no recurrent events at 12 months. A further small study comparing outcomes in those treated with edoxaban (n=20) to warfarin (n=30) following 2 weeks of danaparoid also reported superior clot regression with edoxaban.<sup>50</sup> Although these findings are promising, it is important to note that neither warfarin arm provided standard of care in that there was no bridging until therapeutic INR was reached, with a subtherapeutic INR target (1.5-2.0) in 1 study. This is important as recanalization rates are

**Table 4. Available anticoagulants and considerations for use in management of VTE in CLD**

| Characteristic                       | VKA                                                                           | LMWH                              | Dabigatran                                                                                  | Apixaban                                          | Edoxaban                                                 | Rivaroxaban                                   |
|--------------------------------------|-------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------|----------------------------------------------------------|-----------------------------------------------|
| Dosing                               | Variable od, based on INR                                                     | Weight based, once or twice daily | Twice daily                                                                                 | Twice daily                                       | Once daily                                               | Twice daily for 3 weeks, then once daily      |
| Initiation                           | Overlap with LMWH until INR >2. Use alternate agent if baseline INR increased | As above                          | ≥5 days LMWH, then switch                                                                   | 10mg twice daily for 7 days                       | 5 days LMWH, then switch                                 | 15mg twice daily for 3 weeks                  |
| Standard dose                        | Variable as above                                                             | As above                          | 150mg bd                                                                                    | 5mg twice daily from day 8                        | 60mg od                                                  | 20mg once daily from day 22                   |
| Dose reduction                       | NA                                                                            | CrCl 15–30mL, reduce dose         | 110mg bd for age ≥80 years or concomitant verapamil and consider for other high-risk groups | Consider dose reduction to 2.5mg bd from 6 months | 30mg od for CrCl <50mL/min or weight <60kg               | Consider dose reduction to 10mg from 6 months |
| Drug monitoring                      | Y                                                                             | N                                 | N                                                                                           | N                                                 | N                                                        | N                                             |
| Hepatobiliary/intestinal elimination | Predominant                                                                   | Minimal                           | 20%                                                                                         | 73%                                               | 50%                                                      | 34%                                           |
| CLD                                  |                                                                               |                                   |                                                                                             |                                                   |                                                          |                                               |
| CPC A                                | Y                                                                             | Y                                 | Y                                                                                           | Y                                                 | Cautious, avoid if ALT/AST <2×ULN and bilirubin <1.5×ULN | Y                                             |
| CPC B                                | Y                                                                             | Y                                 | Limited experience, no change in exposure in n=12                                           | Y in absence of coagulopathy                      |                                                          | N                                             |
| CPC C                                | Y                                                                             | Y                                 | N                                                                                           | N                                                 | N                                                        | N                                             |
| CKD                                  |                                                                               |                                   |                                                                                             |                                                   |                                                          |                                               |
| CrCl 15–30mL/min                     | Y                                                                             | ↓Dose                             | Do not use                                                                                  | Limited experience                                | Limited experience                                       | Limited experience                            |
| <15mL/min                            | Y                                                                             | Avoid                             | Do not use                                                                                  | Do not use                                        | Do not use                                               | Do not use                                    |

Modified from Northup et al<sup>60</sup> with permission from Wiley.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; bd, twice daily; CKD, chronic kidney disease; CPC, Child-Pugh classification; CrCl, creatinine clearance; N, no; NA, not applicable; od, once daily; ULN, upper limit of normal; Y, yes.



improved with early anticoagulation.<sup>46</sup> Further adequately powered studies with the use of LMWH bridging until therapeutic INR is achieved in the comparator arm are required. In practice, LMWH is often initiated until completion of upper GI endoscopy, following which a vitamin K antagonist (VKA) can be initiated. DOACs may be a reasonable alternative in cases with difficulty complying to variable dosing of VKA or the monitoring requirements (eg, limited venous access and/or unable to use a point-of-care INR device). For patients with significantly prolonged PT at baseline, I favor extended LMWH provided continued par-enteral administration is acceptable to the patient, given the optimal INR target is unknown in those with significantly raised baseline INR.

For PVT, in which a decision to initiate anticoagulation is made, the minimum recommended duration of anticoagulant therapy is 6 months.<sup>20,37</sup> Guidelines suggest reimaging to evaluate recanalization to guide the ongoing need for anticoagulation.<sup>20</sup> There are, however, no high-quality data to inform whether incomplete recanalization is associated with a higher risk of recurrence or other adverse outcomes related to portal hypertension. Small observational studies suggest the risk of early recurrent PVT is high (up to 38%) following discontinuation of anticoagulation in patients with advanced CLD.<sup>42,46</sup> In addition, previous PVT is a strong predictor for recurrence in prospective observational cohorts.<sup>5</sup> However, given the lack of randomized controlled trials to definitively inform the risk of both PVT recurrence and bleeding, the feasibility of a multicenter prospective study to determine the optimal duration of anticoagulation should be evaluated. Currently, those listed for liver transplantation frequently remain on extended anticoagulation to reduce the risk of recurrent PVT, particularly as the presence of occlusive PVT at transplantation affects both technical success and posttransplant survival.<sup>51</sup> For patients with DVT/pulmonary embolism, the minimum duration of anticoagulation is 3 months. All patients should be reviewed prior to completing 3 months of treatment to consider the need for extended anticoagulation in the presence of persistent risk factors (eg, inflammatory bowel disease) and/or for events not associated with a major provoking factor (eg, major surgery/hospitalization).<sup>52</sup>

## CLINICAL CASE (Continued)

Therapeutic anticoagulation with LMWH was initiated while further endoscopy was planned (unchanged from previous, with no esophageal varices seen with mild portal hypertensive gastropathy). Following this, warfarin was initiated with a target INR of 2.5. LMWH was continued until an INR of more than 2 was achieved. She remained on warfarin for 12 months, and reimaging confirmed partial recanalization of the portal vein. Apart from minor traumatic bruising, there were no significant bleeding complications during treatment.

## Conclusion

In summary, despite frequently deranged hemostatic markers in patients with CLD, there is a dual propensity to bleeding and thrombosis (with a preponderance of portal vein thrombosis). Variceal bleeding secondary to portal hypertension is the

most frequent bleeding manifestation. There is little evidence to support prophylactic correction of hemostatic markers in the periprocedural setting, and use of preemptive transfusion support should be avoided. Anticoagulation is likely to improve outcomes following occlusive portal vein thrombosis, even in the presence of hemostatic abnormalities. However, the optimal duration of anticoagulation and role of DOACs remains uncertain.

## Conflict-of-interest disclosure

Lara N. Roberts: no competing financial interests to declare.

## Off-label drug use

Lara N. Roberts: nothing to disclose.

## Correspondence

Lara N. Roberts, King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; e-mail: [lara.roberts@nhs.net](mailto:lara.roberts@nhs.net).

## References

1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol*. 2006;44(1):217-231.
2. Roberts LN, Bernal W. Incidence of bleeding and thrombosis in patients with liver disease. *Semin Thromb Hemost*. 2020;46(6):656-664.
3. Basili S, Raparelli V, Napoleone L, et al; PRO-LIVER Collaborators. Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER study. *Am J Gastroenterol*. 2018;113(3):368-375.
4. Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. *Ann Hepatol*. 2012;11(5):686-690.
5. Violi F, Corazza GR, Caldwell SH, et al; PRO-LIVER Collaborative Group. Incidence and recurrence of portal vein thrombosis in cirrhotic patients. *Thromb Haemost*. 2019;119(3):496-499.
6. Nery F, Chevret S, Condat B, et al; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. *Hepatology*. 2015;61(2):660-667.
7. Nery F, Correia S, Macedo C, et al. Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. *Aliment Pharmacol Ther*. 2019;49(5):582-588.
8. Noronha Ferreira C, Marinho RT, Cortez-Pinto H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: a prospective study. *Liver Int*. 2019;39(8):1459-1467.
9. Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. *Thromb Haemost*. 2021;19(4):1116-22.
10. Fisher C, Patel VC, Stoy SH, et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. *J Crit Care*. 2018;43:54-60.
11. Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. *J Thromb Haemost*. 2010;8(9):1994-2000.
12. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. *Hepatology*. 2006;44(2):440-445.
13. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. *Hepatology*. 2006;44(1):53-61.
14. Reuken PA, Kussmann A, Kiehntopf M, et al. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. *Liver Int*. 2015;35(1):37-45.
15. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. *Dig Dis Sci*. 1981;26(5):388-393.
16. Vieira da Rocha EC, D'Amico EA, Caldwell SH, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. *Clin Gastroenterol Hepatol*. 2009;7(9):988-993.

17. Napolitano G, Iacobellis A, Merla A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. *Eur J Intern Med.* 2017;38:79-82.
18. Desborough MJ, Hockley B, Sekhar M, et al; National Audit Collaborative. Patterns of blood component use in cirrhosis: a nationwide study. *Liver Int.* 2016;36(4):522-529.
19. Fortea JJ, Puente Á, Ezcurra I, et al. Management of haemostatic alterations and associated disorders in cirrhosis in Spain: a national survey. *Dig Liver Dis.* 2019;51(1):95-103.
20. Northup PG, García-Pagan JC, García-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology.* 2021;73(1):366-413.
21. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. *Hepatology.* 1987;7(1):122-128.
22. Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. *Aliment Pharmacol Ther.* 2005;21(5):525-529.
23. Hung A, García-Tsao G. Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. *Liver Int.* 2018;38(8):1437-1441.
24. Massicotte L, Denault AY, Beaulieu D, et al. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. *Transplantation.* 2012;93(12):1276-1281.
25. Green L, Bolton-Maggs P, Beattie C, et al. British Society of Haematology guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. *Br J Haematol.* 2018;181(1):54-67.
26. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. *Gut.* 1974;15(2):99-101.
27. Rassi AB, d'Amico EA, Tripodi A, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. *J Hepatol.* 2020;72(1):85-94.
28. von Meijenfeldt FA, van den Boom BP, Adelmeijer J, Roberts LN, Lisman T, Bernal W. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. *J Thromb Haemost.* 2021;19(3):664-676.
29. Tripodi A, Primignani M, Chantarangkul V, et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. *Liver Int.* 2013;33(3):362-367.
30. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al; PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. *Lancet.* 2016;387(10038):2605-2613.
31. Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). *Hepatology.* 2019;70(4):1336-1348.
32. Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. *Gastroenterology.* 2018;155(3):705-718.
33. Lindquist I, Olson SR, Li A, et al. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis [published online 18 January 2021]. *Platelets.*
34. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. *Hepatology.* 2003;38(1):258-266.
35. O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. *Gastroenterology.* 2019;157(1):34-43.
36. Patel U, Rahim S, Davidson JC, et al. Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions—part II: recommendations. *J Vasc Interv Radiol.* 2019;30(8):1168-1184.
37. Simonetto DA, Singal AK, García-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. *Am J Gastroenterol.* 2020;115(1):18-40.
38. Ponziani FR, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. *Transplant Rev (Orlando).* 2014;28(2):92-101.
39. Ambrosino P, Tarantino L, Di Minno G, et al. The risk of venous thromboembolism in patients with cirrhosis: a systematic review and meta-analysis. *Thromb Haemost.* 2017;117(1):139-148.
40. Abdel-Razik A, Mousa N, Elhelaly R, Tawfik A. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the model for end-stage liver disease scoring system. *Eur J Gastroenterol Hepatol.* 2015;27(5):585-592.
41. La Mura V, Tripodi A, Tosetti G, et al. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. *Liver Int.* 2016;36(9):1322-1330.
42. Senzolo M, García-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. *J Hepatol.* 2021;75(2):442-453.
43. Wang L, Guo X, Xu X, et al. Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: results of a meta-analysis. *Adv Ther.* 2021;38(1):495-520.
44. Giannini EG, Giambruno E, Brunacci M, et al. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients. *Ann Hepatol.* 2018;17(5):830-835.
45. Bianchini M, Cavani G, Bonaccorso A, et al. Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. *Liver Int.* 2018;38(7):1253-1262.
46. Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. *Clin Gastroenterol Hepatol.* 2012;10(7):776-783.
47. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. *Blood Adv.* 2020;4(19):4693-4738.
48. Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: a systematic review. *Thromb Res.* 2018;170:102-108.
49. Hanafy AS, Abd-El Salam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. *Vascul Pharmacol.* 2019;113:86-91.
50. Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. *Hepatol Res.* 2018;48(1):51-58.
51. Rodríguez-Castro KI, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. *Transplantation.* 2012;94(11):1145-1153.
52. Kearon C, Ageno W, Cannegieter SC, et al; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. *J Thromb Haemost.* 2016;14(7):1480-1483.

© 2021 by The American Society of Hematology  
DOI 10.1182/hematology.2021000283